Cross-species protection mediated by a Bordetella bronchiseptica strain lacking antigenic homologs present in acellular pertussis vaccines

Infection and Immunity

Volumn 78, Issue 5, 2010, Pages 2008-2016

  Sukumar, Neelima ^a   Sloan, Gina Parise ^a   Conover, Matt S ^a   Love, Cheraton F ^a   Mattoo, Seema ^b   Kock, Nancy D ^a   Deora, Rajendar ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE TOXIN; BIPA PROTEIN; MEMBRANE PROTEIN; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; BORDETELLA BRONCHISEPTICA; BORDETELLA BRONCHISEPTICA INFECTION; BORDETELLA PERTUSSIS; CONTROLLED STUDY; FEMALE; LOWER RESPIRATORY TRACT; LUNG INJURY; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTIBODIES, BACTERIAL; BORDETELLA BRONCHISEPTICA; BORDETELLA PERTUSSIS; COLONY COUNT, MICROBIAL; CROSS PROTECTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCYTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICROSCOPY; OPSONIN PROTEINS; PERTUSSIS VACCINE; PHAGOCYTOSIS; RESPIRATORY SYSTEM; VACCINES, ATTENUATED; WHOOPING COUGH;

EID: 77951237313     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01142-09     Document Type: Article

References (57)

1. Altindis, E., B. E. Tefon, V. Yildirim, E. Ozcengiz, D. Becher, M. Hecker, and G. Ozcengiz. 2009. Immunoproteomic analysis of Bordetella pertussis and identification of new immunogenic proteins. Vaccine 27:542-548.
2. Bey, R. F., F. J. Shade, R. A. Goodnow, and R. C. Johnson. 1981. Intranasal vaccination of dogs with liver avirulent Bordetella bronchiseptica: correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis. Am. J. Vet. Res. 42:1130-1132.
3. Bouchez, V., D. Brun, T. Cantinelli, G. Dore, E. Njamkepo, and N. Guiso. 2009. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 27:6034-6041.
4. Bouchez, V., V. Caro, E. Levillain, G. Guigon, and N. Guiso. 2008. Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS One 3:e2437.
5. Brickman, T. J., T. Hanawa, M. T. Anderson, R. J. Suhadolc, and S. K. Armstrong. 2008. Differential expression of Bordetella pertussis iron transport system genes during infection. Mol. Microbiol. 70:3-14.
6. Carbonetti, N. H. 2007. Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease. Curr. Opin. Pharmacol. 7:272-278.
7. Cherry, J. D. 1997. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr. Infect. Dis. J. 16:S90-S96.
8. Cherry, J. D. 1999. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin. Infect. Dis. 28(Suppl. 2):S112-S117.
9. Cherry, J. D. 2005. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 115:1422-1427.
10. Cherry, J. D. 1998. Pertussis in adults. Ann. Intern. Med. 128:64-66.
11. Cherry, J. D., and P. Olin. 1999. The science and fiction of pertussis vaccines. Pediatrics 104:1381-1383.
12. Cotter, P. A., M. H. Yuk, S. Mattoo, B. J. Akerley, J. Boschwitz, D. A. Relman, and J. F. Miller. 1998. Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization. Infect. Immun. 66:5921-5929.
13. Cummings, C. A., M. M. Brinig, P. W. Lepp, S. van de Pas, and D. A. Relman. 2004. Bordetella species are distinguished by patterns of substantial gene loss and host adaptation. J. Bacteriol. 186:1484-1492.
14. Edinboro, C. H., M. P. Ward, and L. T. Glickman. 2004. A placebo-controlled trial of two intranasal vaccines to prevent tracheobronchitis (kennel cough) in dogs entering a humane shelter. Prev. Vet. Med. 62:89-99.
15. Eldering, G., and P. Kendrick. 1938. Bacillus para-pertussis: a species resembling both Bacillus pertussis and Bacillus bronchisepticus but identical with neither. J. Bacteriol. 35:561-572.
16. Eldering, G., and P. L. Kendrick. 1952. Incidence of parapertussis in the Grand Rapids area as indicated by 16 years' experience with diagnostic cultures. Am. J. Public Health Nations Health 42:27-31.
17. Fuchslocher, B., L. L. Millar, and P. A. Cotter. 2003. Comparison of bipA alleles within and across Bordetella species. Infect. Immun. 71:3043-3052.
18. Gilberg, S., E. Njamkepo, I. P. Du Chatelet, H. Partouche, P. Gueirard, C. Ghasarossian, M. Schlumberger, and N. Guiso. 2002. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J. Infect. Dis. 186:415-418.
19. Goodnow, R. A. 1980. Biology of Bordetella bronchiseptica. Microbiol. Rev. 44:722-738.
20. Gopinathan, L., G. S. Kirimanjeswara, D. N. Wolfe, M. L. Kelley, and E. T. Harvill. 2007. Different mechanisms of vaccine-induced and infection-induced immunity to Bordetella bronchiseptica. Microbes Infect. 9:442-448.
21. Gross, R., and R. Rappuoli. 1988. Positive regulation of pertussis toxin expression. Proc. Natl. Acad. Sci. U. S. A. 85:3913-3917.
22. Harvill, E. T., P. A. Cotter, and J. F. Miller. 1999. Pregenomic comparative analysis between Bordetella bronchiseptica RB50 and Bordetella pertussis Tohama I in murine models of respiratory tract infection. Infect. Immun. 67:6109-6118.
23. Hewlett, E. L., G. M. Donato, and M. C. Gray. 2006. Macrophage cytotoxicity produced by adenylate cyclase toxin from Bordetella pertussis: more than just making cyclic AMP! Mol. Microbiol. 59:447-459.
24. Higgins, S. C., A. G. Jarnicki, E. C. Lavelle, and K. H. Mills. 2006. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J. Immunol. 177:7980-7989.
25. Kirimanjeswara, G. S., P. B. Mann, and E. T. Harvill. 2003. Role of antibodies in immunity to Bordetella infections. Infect. Immun. 71:1719-1724.
26. Le, T., J. D. Cherry, S. J. Chang, M. D. Knoll, M. L. Lee, S. Barenkamp, D. Bernstein, R. Edelman, K. M. Edwards, D. Greenberg, W. Keitel, J. Treanor, and J. I. Ward. 2004. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. J. Infect. Dis. 190:535-544.
27. Locht, C. 2008. A common vaccination strategy to solve unsolved problems of tuberculosis and pertussis? Microbes Infect. 10:1051-1056.
28. Mann, P., E. Goebel, J. Barbarich, M. Pilione, M. Kennett, and E. Harvill. 2007. Use of a genetically defined double mutant strain of Bordetella bronchiseptica lacking adenylate cyclase and type III secretion as a live vaccine. Infect. Immun. 75:3665-3672.
29. Marr, N., D. C. Oliver, V. Laurent, J. Poolman, P. Denoel, and R. C. Fernandez. 2008. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. Vaccine 26:4306-4311.
30. Mattoo, S., and J. D. Cherry. 2005. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18:326-382. (Pubitemid 40548297)
31. Mattoo, S., J. F. Miller, and P. A. Cotter. 2000. Role of Bordetella bronchiseptica fimbriae in tracheal colonization and development of a humoral immune response. Infect. Immun. 68:2024-2033.
32. McArthur, J. D., N. P. West, J. N. Cole, H. Jungnitz, C. A. Guzman, J. Chin, P. R. Lehrbach, S. P. Djordjevic, and M. J. Walker. 2003. An aromatic amino acid auxotrophic mutant of Bordetella bronchiseptica is attenuated and immunogenic in a mouse model of infection. FEMS Microbiol. Lett. 221:7-16.
33. Medhekar, B., R. Shrivastava, S. Mattoo, M. Gingery, and J. F. Miller. 2009. Bordetella Bsp22 forms a filamentous type III secretion system tip complex and is immunoprotective in vitro and in vivo. Mol. Microbiol. 71:492-504.
34. Mielcarek, N., A. S. Debrie, D. Raze, J. Bertout, C. Rouanet, A. B. Younes, C. Creusy, J. Engle, W. E. Goldman, and C. Locht. 2006. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2:e65.
35. Mielcarek, N., A. S. Debrie, D. Raze, J. Quatannens, J. Engle, W. E. Goldman, and C. Locht. 2006. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation. Vaccine 24(Suppl. 2):S2-54-S2-55.
36. Mills, K. H., M. Ryan, E. Ryan, and B. P. Mahon. 1998. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66:594-602.
37. Mishra, M., G. Parise, K. D. Jackson, D. J. Wozniak, and R. Deora. 2005. The BvgAS signal transduction system regulates biofilm development in Bordetella. J. Bacteriol. 187:1474-1484. (Pubitemid 40299471)
38. Mooi, F. R., I. H. van Loo, M. van Gent, Q. He, M. J. Bart, K. J. Heuvelman, S. C. de Greeff, D. Diavatopoulos, P. Teunis, N. Nagelkerke, and J. Mertsola. 2009. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg. Infect. Dis. 15:1206-1213.
39. Nicholson, T. L., S. L. Brockmeier, and C. L. Loving. 2009. Contribution of Bordetella bronchiseptica filamentous hemagglutinin and pertactin to respiratory disease in swine. Infect. Immun. 77:2136-2146.
40. Parise, G., M. Mishra, Y. Itoh, T. Romeo, and R. Deora. 2007. Role of a putative polysaccharide locus in Bordetella biofilm development. J. Bacteriol. 189:750-760.
41. Parkhill, J., M. Sebaihia, A. Preston, L. D. Murphy, N. Thomson, D. E. Harris, M. T. Holden, C. M. Churcher, S. D. Bentley, K. L. Mungall, A. M. Cerdeno-Tarraga, L. Temple, K. James, B. Harris, M. A. Quail, M. Achtman, R. Atkin, S. Baker, D. Basham, N. Bason, I. Cherevach, T. Chillingworth, M. Collins, A. Cronin, P. Davis, J. Doggett, T. Feltwell, A. Goble, N. Hamlin, H. Hauser, S. Holroyd, K. Jagels, S. Leather, S. Moule, H. Norberczak, S. O'Neil, D. Ormond, C. Price, E. Rabbinowitsch, S. Rutter, M. Sanders, D. Saunders, K. Seeger, S. Sharp, M. Simmonds, J. Skelton, R. Squares, S. Squares, K. Stevens, L. Unwin, S. Whitehead, B. G. Barrell, and D. J. Maskell. 2003. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat. Genet. 35:32-40.
42. Porter, J. F., K. Connor, and W. Donachie. 1994. Isolation and characterization of Bordetella parapertussis-like bacteria from ovine lungs. Microbiology 140:255-261.
43. Schlageter, A. M., and T. R. Kozel. 1990. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect. Immun. 58:1914-1918.
44. Spears, P. A., L. M. Temple, D. M. Miyamoto, D. J. Maskell, and P. E. Orndorff. 2003. Unexpected similarities between Bordetella avium and other pathogenic bordetellae. Infect. Immun. 71:2591-2597.
45. Stainer, D. W., and M. J. Scholte. 1970. A simple chemically defined medium for the production of phase I Bordetella pertussis. J. Gen. Microbiol. 63:211-220.
46. Stevenson, A., and M. Roberts. 2004. Intranasal immunisation against tetanus with an attenuated Bordetella bronchiseptica vector expressing FrgC: improved immunogenicity using a Bvg-regulated promoter to express FrgC. Vaccine 22:4300-4305.
47. Stevenson, A., and M. Roberts. 2002. Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens. Vaccine 20:2325-2335. (Pubitemid 34497043)
48. Stevenson, A., and M. Roberts. 2003. Use of Bordetella bronchiseptica and Bordetella pertussis as live vaccines and vectors for heterologous antigens. FEMS Immunol. Med. Microbiol. 37:121-128.
49. Stockbauer, K. E., B. Fuchslocher, J. F. Miller, and P. A. Cotter. 2001. Identification and characterization of BipA, a Bordetella Bvg-intermediate phase protein. Mol. Microbiol. 39:65-78.
50. Sukumar, N., C. F. Love, M. S. Conover, N. D. Kock, P. Dubey, and R. Deora. 2009. Active and passive immunizations with Bordetella colonization factor A protect mice against respiratory challenge with Bordetella bronchiseptica. Infect. Immun. 77:885-895.
51. Sukumar, N., M. Mishra, G. P. Sloan, T. Ogi, and R. Deora. 2007. Differential Bvg phase-dependent regulation and combinatorial role in pathogenesis of two Bordetella paralogs, BipA and BcfA. J. Bacteriol. 189:3695-3704.
52. Temple, L. M., A. A. Weiss, K. E. Walker, H. J. Barnes, V. L. Christensen, D. M. Miyamoto, C. B. Shelton, and P. E. Orndorff. 1998. Bordetella avium virulence measured in vivo and in vitro. Infect. Immun. 66:5244-5251.
53. Vergara-Irigaray, N., A. Chavarri-Martinez, J. Rodriguez-Cuesta, J. F. Miller, P. A. Cotter, and G. Martinez de Tejada. 2005. Evaluation of the role of the Bvg intermediate phase in Bordetella pertussis during experimental respiratory infection. Infect. Immun. 73:748-760.
54. Vojtova, J., J. Kamanova, and P. Sebo. 2006. Bordetella adenylate cyclase toxin: a swift saboteur of host defense. Curr. Opin. Microbiol. 9:69-75.
55. Wendelboe, A. M., M. G. Hudgens, C. Poole, and A. Van Rie. 2007. Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants. Emerg. Themes Epidemiol. 4:15.
56. Wendelboe, A. M., E. Njamkepo, A. Bourillon, D. D. Floret, J. Gaudelus, M. Gerber, E. Grimprel, D. Greenberg, S. Halperin, J. Liese, F. Munoz-Rivas, R. Teyssou, N. Guiso, and A. Van Rie. 2007. Transmission of Bordetella pertussis to young infants. Pediatr. Infect. Dis. J. 26:293-299.
57. Wilson, T. R. 2006. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis. J. Pediatr. Health Care 20:229-237.